Filing Flows › Halozyme Therapeutics (HALO) › R&D spending
Halozyme Therapeutics (HALO) R&D spending by quarter
Halozyme Therapeutics' R&D spending was $27.8M in Q3 2026 (third quarter 2026), +0.4% from Q2 2026. Over the last 7 quarters it ranged from $14.8M (Q1 2025) to $31.9M (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $27.8M | +0.4% | +61% |
| Q2 2026 | $27.7M | +8% | +58% |
| Q1 2026 | $25.6M | -20% | +73% |
| Q4 2025 | $31.9M | +85% | — |
| Q3 2025 | $17.3M | -2% | — |
| Q2 2025 | $17.5M | +19% | — |
| Q1 2025 | $14.8M | — | — |
Q3 2026 at a glance
Halozyme Therapeutics, Q3 2026: revenue $493M (+39% year over year), operating margin 59.8%, net earnings $247M, operating cash flow $258M. The chart follows the revenue to costs, profit and cash.
Questions
What is Halozyme Therapeutics' R&D spending?
Halozyme Therapeutics' R&D spending was $27.8M in Q3 2026 (third quarter 2026), +0.4% from Q2 2026.
How has Halozyme Therapeutics' R&D spending changed?
Over the last 7 quarters it ranged from $14.8M (Q1 2025) to $31.9M (Q4 2025).